

DAFTAR PUSTAKA

- Al-Bahlani, S. M., Al-Bulushi, K. H., Al-Alawi, Z. M., Al-Abri, N. Y., Al-Hadidi, Z. R., & Al-Rawahi, S. S. 2017. Cisplatin Induces Apoptosis Through the Endoplasmic Reticulum-mediated, Calpain 1 Pathway in Triple-negative Breast Cancer Cells. *Clinical Breast Cancer*. 17(3), e103–e112. doi:10.1016/j.clbc.2016.12.001
- Aggarwal BB, Kumar A, Bharti AC. 2003. Anticancer potential of curcumin: preclinical and clinical studies. *Anticancer Res*. 23:363–398.
- Aggarwal BB, Sundaram C, Malani N, Ichikawa H. 2007. Curcumin: The Indian solid gold. *Adv Exp Med Biol*. 595:1–75.
- Amberger JS, Bocchini CA, Scott AF, Hamosh A. 2019. OMIM.org: leveraging knowledge across phenotype-gene relationships. *Nucleic Acids Res* Jan 8;47(D1):D1038-D1043. doi: 10.1093/nar/gky1151. PMID: 30445645; PMCID: PMC6323937.
- An, X., Xu, F., Luo, R., Zheng, Q., Lu, J., Yang, Y., Wang, S. 2018. The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer. *BMC Cancer*. 18(1). doi:10.1186/s12885-018-4170-7
- Anait, S., and Jordan, V. C. 1997. ‘MCF-7: the first hormone-responsive breast cancer cell line. *Canc Res*. 57 : 3 071–8.
- Anaya, J. 2016. OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs. *PeerJ Computer Science*. <https://doi.org/10.7717/peerj-cs.67>
- Awale, M., Reymond, JL. 2017. The polypharmacology browser: a web-based multi-fingerprint target prediction tool using ChEMBL bioactivity data. *J Cheminform*. 9, 11. <https://doi.org/10.1186/s13321-017-0199-x>
- Ayoub, N. M. 2021. Editorial: Novel Combination Therapies for the Treatment of Solid Cancers. *Front Oncol*. 11:708943. doi: 10.3389/fonc.2021.708943. PMID: 34222030; PMCID: PMC8250861.
- Bahar, M.E., Kim, H.J. & Kim, D.R. 2023. Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies. *Sig Transduct Target Ther*. 8, 455. <https://doi.org/10.1038/s41392-023-01705-z>

- Barry J., Fritz M., Brender J.R., Smith P.E., Lee D.K., Ramamoorthy A. 2009. Determining the effects of lipophilic drugs on membrane structure by solid-state NMR spectroscopy: The case of the antioxidant curcumin. *J. Am. Chem. Soc.* 131:4490–4498. doi: 10.1021/ja809217u.
- Basu, A., & Krishnamurthy, S. 2010. Cellular Responses to Cisplatin-Induced DNA Damage. *Journal of Nucleic Acids.* 1–16. doi:10.4061/2010/201367
- Blagosklonny, M.V. 2004. Analysis of FDA approved anticancer drugs reveals the future of cancer therapy. *Cell Cycle.* (3):1035–42.
- Bozko, P., Larsen, A. K., Raymond, E., & Skladanowski, A. 2002. Influence of G2 arrest on the cytotoxicity of DNA topoisomerase inhibitors toward human carcinoma cells with different p53 status. *Acta Biochimica Polonica,* 49(1), 109–119. https://doi.org/10.18388/abp.2002_3827
- Calaf GM, Ponce-Cusi R, Carrión F. 2018. Curcumin and paclitaxel induce cell death in breast cancer cell lines. *Oncol Rep.* 40(4):2381-2388. doi: 10.3892/or.2018.6603. Epub 2018 Jul 26. PMID: 30066930.
- Callari, M., Sola, M., Magrin, C. 2023. Cancer-specific association between Tau (MAPT) and cellular pathways, clinical outcome, and drug response. *Sci Data.* 10, 637. <https://doi.org/10.1038/s41597-023-02543-y>
- Cao, J., Wang, H., Chen, F., Fang, J., Xu, A., Xi, W., Zhang, S., Wu, G., Wang, Z. 2016. Galangin inhibits cell invasion by suppressing the epithelial-mesenchymal transition and inducing apoptosis in renal cell carcinoma. *Molecular Medicine Reports.* 13(5): 4238-4244.
- Chandrashekar, D. S., Bashel, B., Balasubramanya, S. A. H., Creighton, C. J., Ponce-Rodriguez, I., Chakravarthi, B. V. S. K., & Varambally, S. 2017. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. *Neoplasia.* 19(8), 649–658. doi:10.1016/j.neo.2017.05.002
- Chen D, Li D, Xu XB, Qiu S, Luo S, Qiu E, Rong Z, Zhang J, Zheng D. 2019. Galangin inhibits epithelial-mesenchymal transition and angiogenesis by downregulating CD44 in glioma. *J Cancer.* 10:4499–508.
- Chiang, KC., Tsui, KH., Chung, LC. 2014. Cisplatin modulates B-cell translocation gene 2 to attenuate cell proliferation of prostate carcinoma cells in both p53-dependent and p53-independent pathways. *Sci Rep.* 4, 5511. <https://doi.org/10.1038/srep05511>

- Choi YJ, Lee YH, Lee ST. 2015. Galangin and kaempferol suppress phorbol-12-myristate-13-acetate-induced matrix metalloproteinase-9 expression in human fibrosarcoma HT-1080 cells. *Mol Cells*. 38:151–5
- Clementi L, Sabetta S, Zelli V, Compagnoni C, Tessitore A, Mattei V, Angelucci A. 2023. Mitotic phosphorylation of Tau/MAPT modulates cell cycle progression in prostate cancer cells. *J Cancer Res Clin Oncol*. 149(10):7689-7701. doi: 10.1007/s00432-023-04721-2. Epub 2023 Mar 31. PMID: 37000265; PMCID: PMC10374748.
- Cleveland D.W., Hwo S.Y., Kirschner M.W. 1977. Purification of Tau, a Microtubule-Associated Protein That Induces Assembly of Microtubules from Purified Tubulin. *J. Mol. Biol.* 116:207–225. doi: 10.1016/0022-2836(77)90213-3.
- Coronel-Hernández J, Salgado-García R, Cantú-De León D, Jacobo-Herrera N, Millan-Catalan O, Delgado-Waldo I, Campos-Parra AD, Rodríguez-Morales M, Delgado-Buenrostro NL, Pérez-Plasencia C. 2021. Combination of Metformin, Sodium Oxamate and Doxorubicin Induces Apoptosis and Autophagy in Colorectal Cancer Cells via Downregulation HIF-1 α . *Front Oncol*. 11:594200. doi: 10.3389/fonc.2021.594200. PMID: 34123772; PMCID: PMC8187873.
- Cunha, J. P. 2023. Cisplatin. <https://www.rxlist.com/cisplatin-drug.htm#description>.
- Daenthanasanmak A, Bamford RN, Yoshioka M, Yang SM, Homan P, Karim B, Bryant BR, Petrus MN, Thomas CJ, Green PL, Miljkovic MD, Conlon KC, Waldmann TA. 2022. Triple combination of BET plus PI3K and NF- κ B inhibitors exhibit synergistic activity in adult T-cell leukemia/lymphoma. *Blood Adv*. 6(7):2346-2360. doi: 10.1182/bloodadvances.2021005948. PMID: 35030628; PMCID: PMC9006306.
- Daina, A., Michielin, O., Zoete, V. 2019. SwissTargetPrediction: Updated data and new features for efficient prediction of protein targets of small molecules. *Nucleic Acids Res*. 47, W357–W364.
- Dana Farber. 2022. Three-drug combination slows progression of advanced kidney cancer. <https://www.dana-farber.org/newsroom/news-releases/2022/three-drug-combination-slows-progression-of-advanced-kidney-cancer>. Accessed April 14, 2024.

- Dasari, S., and Tchounwou, P.B. 2014. Cisplatin in cancer therapy: molecular mechanisms of action. *Eur. J. Pharmacol.* 740 , pp. 364-378.
- Davis, A.P., Grondin, C.J., Johnson, R.J., Sciaky, D. , McMorran, R., Wieggers, J., Wieggers, T. C., Mattingly, C.J. (2019). The comparative toxicogenomics database: update 2019. *Nucleic Acids Res.* 47, D948–D954, <https://doi.org/10.1093/nar/gky868>.
- Da'i, M., Jenie, A.A., Supardjan, A.M, Meiyanto, E., dan Kawaichi, M. 2012. The Effect of PGV-1, PGV-0 and Curcumin on Protein Involve in G2-M Phase of Cell Cycle and Apoptosis on T47D Breast Cancer Cell Line. *Jurnal Ilmu Kefarmasian Indonesia.* 10(2):99-110.
- Da'i, M., Suhendi, A., Meiyanto, E., Jenie, U. A., & Kawaichi, M. 2017. Apoptosis Induction Effect of Curcumin and its Analogs Pentagamavunon-0 and Pentagamavunon-1 on Cancer Cell Lines. *Asian Journal of Pharmaceutical and Clinical Research.* 10(3), 373. doi:10.22159/ajpcr.2017.v10i3.163
- De Angelis, P. M., Svendsrud, D. H., Kravik, K. L., & Stokke, T. 2006. Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. *Molecular Cancer,* 5, 1–25. <https://doi.org/10.1186/1476-4598-5-20>
- Devadoss D, Ramar M, Chinnasamy A. 2018. Galangin, a dietary flavonol inhibits tumor initiation during experimental pulmonary tumorigenesis by modulating xenobiotic enzymes and antioxidant status. *Arch Pharm Res.* 41:265–75.
- Edityaningrum, C. A., Khairurrizki, A., Nurani, L. H., Bachri, M. S., Supto Yuliani, D. U., Kintoko, Nurkhasanah, Irham, L. M., & Zakaria, Z. A. 2024. Co-Chemotherapy Effect of The Extract of Hibiscus Sabdariffa and Cisplatin Against Apoptosis and Anti-Proliferation on T47d and Vero Cells. *Tropical Journal of Natural Product Research (TJNPR).* 8(6), 7509-7513. <https://doi.org/10.26538/tjnpr/v8i6.27>
- Endah, E., Wulandari, F., Putri, Y.M., Jenie, R.I., Meiyanto, E. 2022. Piperine Increases Pentagamavunone-1 Anti-cancer Activity on 4T1 Breast Cancer through Mitotic Catastrophe Mechanism and Senescence with Sharing Targeting on Mitotic Regulatory Proteins. *Iran. J. Pharm. Res.* 21, 1–15. <https://doi.org/10.22037/ijpr.2021.115723.15488>.

- Fattah A, Morovati A, Niknam Z, Mashouri L, Asadi A, Tvangar Rizi S, Abbasi M, Shakeri F, Abazari O. 2021. The Synergistic Combination of Cisplatin and Piperine Induces Apoptosis in MCF-7 Cell Line. *Iran J Public Health*. 50(5):1037-1047.
- Feng Y, Thiagarajan PS, Ma PC. 2012. MET signaling: novel targeted inhibition and its clinical development in lung cancer. *J Thorac Oncol*. 7(2):459-67. doi: 10.1097/JTO.0b013e3182417e44. PMID: 22237263
- Ferlay J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Bray, F. 2015. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *International Journal of Cancer*. 136(5), E359-86. <https://doi.org/10.1002/ijc.29210>.
- Ferlay J, Laversanne M, Ervik M, Lam F, Colombet M, Mery L, et al. Global Cancer Observatory: Cancer Tomorrow. In: Lyon, France: International Agency for Research on Cancer. [Internet]. 2020. [cited 13 April 2024]. Available: <https://gco.iarc.fr/tomorrow>.
- Florea, M.A. and Busselberg, D. 2011. Cisplatin as an Anti-Tumor Drug : Cellular Mechanism of Activity, Drug Resistance and Induced Side Effects. *Cancer*. 3(4), 1351–1371.
- Fountzilas, G., Valavanis, C., Kotoula, V., Eleftheraki, A.G., Kalogeras, K.T., Tzaida, O., Batistatou, A., Kronenwett, R., Wirtz, R.M., Bobos, M., Timotheadou, E., Soupos, N., Pentheroudakis, G., Gogas, H., Vlachodimitropoulos, D., Polychronidou, G., Aravantinos, G., Koutras, A., Christodoulou, C., Pectasides, D., Arapantoni, P. 2012. HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. *J Transl Med*. 10, 10. <https://doi.org/10.1186/1479-5876-10-10>
- Fuertes MA, Castilla J, Alonso C, Pérez JM. 2003. Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. *Curr Med Chem*. 10(3):257-66. doi: 10.2174/0929867033368484. PMID: 12570712.
- Gale, R. P. 2022. Combination Cancer Therapy. URL <https://www.merckmanuals.com/home/cancer/prevention-and-treatment-of-cancer/combo-cancer-therapy> (accessed April 14, 2024).

- Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. 2012. Molecular mechanisms of cisplatin resistance. *Oncogene*. 31(15):1869-83. doi: 10.1038/onc.2011.384. Epub 2011 Sep 5. PMID: 21892204.
- Ge, S. X., Jung, D., Yao, R. 2020. ShinyGO: A Graphical Gene-Set Enrichment Tool for Animals and Plants. *Bioinformatics*. 36, 2628– 2629, DOI: 10.1093/bioinformatics/btz931.
- Gfeller, D., Grosdidier, A., Wirth, M., Daina, A., Michielin, O., & Zoete, V. 2014. SwissTargetPrediction: a web server for target prediction of bioactive small molecules. *Nucleic Acids Research*. 42(W1), W32–W38. doi:10.1093/nar/gku293
- Gomes L.R., Rocha C.R.R., Martins D.J., Fiore A.P.Z.P., Kinker G.S., Bruni-Cardoso A., Menck C.F.M. 2019. ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation. *Cell Death Dis*. 10:1–15. doi: 10.1038/s41419-019-1689-8.
- Hamami, S. M. A., Fai, M., Aththar, A. F., Zakaria, M. N. Z., Kharisma, V. D., Murtadlo, A. A. A., Tamam, M. B., Jakhmola, V., Widyananda, M. H., & Turista, D. D. R. 2022. Nano Transdermal Delivery Potential of Fucoïdan from *Sargassum* sp.(Brown Algae) as Chemoprevention Agent for Breast Cancer Treatment. *Pharmacognosy Journal*. 14(6). DOI:10.5530/pj.2022.14.169
- Hankittichai P, Thaklaewphan P, Wikan N, Ruttanapattanakul J, Potikanond S, Smith DR, Nimlamool W. 2023. Resveratrol Enhances Cytotoxic Effects of Cisplatin by Inducing Cell Cycle Arrest and Apoptosis in Ovarian Adenocarcinoma SKOV-3 Cells through Activating the p38 MAPK and Suppressing AKT. *Pharmaceuticals (Basel)*. 16(5):755. doi: 10.3390/ph16050755. PMID: 37242538; PMCID: PMC10220637.
- Hasbiyani, N.A.F., Meiyanto, E., Hermawan, A., Wulandari, F., and Nugroho, E.P. 2021. Bioinformatics Analysis Confirms the Target Protein Underlying Mitotic Catastrophe of 4T1 Cells under Combinatorial Treatment of PGV-1 and Galangin. *Sci. Pharm.* 89(3), 38; <https://doi.org/10.3390/scipharm89030038>.
- Haura EB. 2006. SRC and STAT pathways. *J Thorac Oncol*. 1(5):403-5. PMID: 17409890.
- He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW, Li B. 2021. Targeting PI3K/Akt signal transduction for cancer therapy. *Signal Transduct Target Ther*. 6(1):425. doi:

10.1038/s41392-021-00828-5. PMID: 34916492; PMCID: PMC8677728.

- Hermawan, A., Fitriasari, A., Junedi, S., Ikawati, M., Haryanti, S., Widaryanti, B., Da'i, M., & Meiyanto, E. 2011. PGV-0 and PGV-1 Increased Apoptosis Induction of Doxorubicin on MCF-7 Breast Cancer cells. *Pharmaceutical Journal of Indonesia*. 11(2), 10–14. <https://doi.org/10.16194/j.cnki.31-1059/g4.2011.07.016>.
- Hermawan, A., Putri, H., Fatimah, N., Prasetyo, H. H. 2024. Transcriptomics analysis reveals distinct mechanism of breast cancer stem cells regulation in mammospheres from MCF-7 and T47D cells. *Heliyon*. 10(2), doi: <https://doi.org/10.1016/j.heliyon.2024.e24356>.
- Hernández, J.L., Padilla, L., Dakhel, S., Coll, T., Hervas, R., Adan, J., Masa, M., Mitjans, F., Martinez, J.M., Coma, S., Rodríguez, L., Noé, V., Ciudad, C.J., Blasco, F., Messeguer, R. 2013. Therapeutic Targeting of Tumor Growth and Angiogenesis with a Novel Anti-S100A4 Monoclonal Antibody. *PLoS ONE*. 8, e72480. <https://doi.org/10.1371/journal.pone.0072480>.
- Higgins MJ, Stearns V. 2009. Understanding Resistance to Tamoxifen in Hormone Receptor-Positive Breast Cancer. *Clini Chem*. 55(8):1453–1455. <https://doi.org/10.1373/clinchem.2009.125377>.
- Huang H, Chen AY, Rojanasakul Y, Ye X, Rankin GO, Chen YC. 2015. Dietary compounds galangin and myricetin suppress ovarian cancer cell angiogenesis. *J Funct Foods*. 15:464–75.
- Huang L, Lin M, Zhong X, Yang H, Deng M. 2019. Galangin decreases p-tau, A β 42 and β -secretase levels, and suppresses autophagy in okadaic acid-induced PC12 cells via an Akt/GSK3 β /mTOR signaling-dependent mechanism. *Mol Med Rep*. 19(3):1767-1774. doi: 10.3892/mmr.2019.9824. Epub 2019 Jan 4. PMID: 30628698.
- Huang, H., Chen, A.Y, Ye, X., Guan, R., Rankin, G.O., dan Chen, Y.C. 2020. Galangin, a Flavonoid from Lesser Galangal, Induced Apoptosis via p53-Dependent Pathway in Ovarian Cancer Cells. *Molecules*. 25(7):1579. doi: 10.3390/molecules25071579. PMID: 32235536; PMCID: PMC7180956.
- Ibar, C., Glavic, Á. 2017. Drosophila p115 is required for Cdk1 activation and G2/M cell cycle transition. *Mech Dev*. 144, 191-200. <https://doi.org/10.1016/j.mod.2017.04.001>
- Iglesias P, Seoane M, Golán I, Castro-Piedras I, Fraga M, Arce VM, Costoya JA. 2020. PARP1 Deficiency Reduces Tumour Growth by

- Decreasing E2F1 Hyperactivation: A Novel Mechanism in the Treatment of Cancer. *Cancers (Basel)*. 10;12(10):2907. doi: 10.3390/cancers12102907. PMID: 33050515; PMCID: PMC7599842.
- Ikawati, M., Utomo, R.Y., Hapsari, N.P., Meiyanto, E., and Oka, C. 2024. Diosmin Enhances the Anti-migration Activity of Curcumin Analog PGV-1 on Colorectal Cancer Cell. *The Indonesian Biomedical Journal*. 16(1):56-65. doi: 10.18585/inabj.v16i1.2829.
- Jaiswal, J.V., Wadegaonkar, P.A. & Hajare, S.W. 2012. The Bioflavonoid Galangin Suppresses the Growth of Ehrlich Ascites Carcinoma in Swiss Albino Mice: A Molecular Insight. *Appl Biochem Biotechnol*. 167, 1325–1339. <https://doi.org/10.1007/s12010-012-9646>
- Jiménez-Santos, M. J., García-Martín, S., Fustero-Torre, C., Domenico, T. D., Gómez-López, G., & Al-Shahrour, F. 2022. Bioinformatics roadmap for therapy selection in cancer genomics. *Molecular Oncology*. 16(21), 3881-3908. <https://doi.org/10.1002/1878-0261.13286>
- Kazemi S, Asadi F, Barari L, Morakabati P, Jahani M, Kani SNM, Soorani F, Kolangi F, Memariani Z. 2021. Quantification of flavonoids in alpinia officinarum hance. via HPLC and evaluation of its cytotoxicity on human prostate carcinoma (LNCaP) and breast carcinoma (MCF-7) cells. *Acamc*. doi: 10.2174/1871520621666210706142157.
- Khamis, A. A. A., Ali, E. M. M., El-Moneim, M. A. A., Abd-Alhaseeb, M. M., El-Magd, M. A., & Salim, E. I. 2018. Hesperidin, piperine and bee venom synergistically potentiate the anticancer effect of tamoxifen against breast cancer cells. *Biomedicine & Pharmacotherapy*. 105, 1335–1343. doi:10.1016/j.biopha.2018.06.1
- Kim, S. B., Kim, J. S., Lee, J. H., Yoon, W. J., Lee, D. S., Ko, M. S., Park, J. W. 2005. NF-κB activation is required for cisplatin-induced apoptosis in head and neck squamous carcinoma cells. *FEBS Letters*. 580(1), 311–318. doi:10.1016/j.febslet.2005.12.
- Kip B, Tunc CU, Aydin O. 2022. Triple-combination therapy assisted with ultrasound-active gold nanoparticles and ultrasound therapy against 3D cisplatin-resistant ovarian cancer model. *Ultrason Sonochem*. 82:105903. doi: 10.1016/j.ultsonch.2021.105903. Epub 2021 Dec 29. PMID: 34974392; PMCID: PMC8799745.

- Leal-Esteban, L.C., Fajas, L., 2020. Cell cycle regulators in cancer cell metabolism. *Biochim. Biophys. Acta BBA - Mol. Basis Dis.* 1866, 165715. <https://doi.org/10.1016/j.bbadis.2020.165715>
- LeBaron, S., Zeltzer, L.K., LeBaron, C., Scott, S.E., Zeltzer, P.M. 1988. Chemotherapy side effects in pediatric oncology patients: drugs, age, and sex as risk factors. *Med Pediatr Oncol.* (16):263–8.
- Lee, C.C., Lin, M.L., Meng, M., Chen, S.S. 2018. Galangin induces p53-independent S-phase arrest and apoptosis in human nasopharyngeal carcinoma cells through inhibiting PI3K/AKT signaling pathway. *Anticancer Research.* 38, 1377-1389. <https://doi.org/10.21873/anticancerres.12361>
- Lefebvre, J. and Glezerman, I. G. 2019. Chapter 217- Anticancer Drugs and the Kidney. *Critical Care Nephrology (Third Edition).* Elsevier. Pages 1302-1305.e2, ISBN 9780323449427, <https://doi.org/10.1016/B978-0-323-44942-7.00217-X>.
- Lehár J, Krueger AS, Avery W, Heilbut AM, Johansen LM, Price ER, Rickles RJ, Short GF 3rd, Staunton JE, Jin X, Lee MS, Zimmermann GR, Borisy AA. 2009. Synergistic drug combinations tend to improve therapeutically relevant selectivity. *Nat Biotechnol.* 27(7):659-66. doi: 10.1038/nbt.1549. Epub 2009 Jul 5. Erratum in: *Nat Biotechnol.* 2009 Sep;27(9):864. PMID: 19581876; PMCID: PMC2708317.
- Lesk, A.M. 2025. bioinformatics. *Encyclopedia Britannica.* <https://www.britannica.com/science/bioinformatics>. Diakses pada 5 April 2025.
- Lestari B, Nakamae I, Yoneda-Kato N, Morimoto T, Kanaya S, Yokoyama T. 2019. Pentagamavunon-1 (PGV-1) inhibits ROS metabolic enzymes and suppresses tumor cell growth by inducing M phase (prometaphase) arrest and cell senescence. *Sci Rep.* 9(1): 14867. doi: 10.1038/s41598-019-51244-3.
- Li, X., Mu, P., Qiao, H., Wen, J., & Deng, Y. 2018. JNK-AKT-NF-κB controls P-glycoprotein expression to attenuate the cytotoxicity of Deoxynivalenol in mammalian cells. *Biochemical Pharmacology.* doi:10.1016/j.bcp.2018.08.020
- Liang X, Wang P, Yang C, Huang F, Wu H, Shi H, Wu X. 2021. Galangin inhibits gastric cancer growth through enhancing STAT3 mediated ROS production. *Front Pharmacol.* 12:646628.

- Lim, S., Kaldis, P., 2013. Cdks, cyclins and CKIs: roles beyond cell cycle regulation. *Development* 140, 3079-3093. <https://doi.org/10.1242/dev.091744>
- Liu, D., You, P., Luo, Y., Yang, M., & Liu, Y. 2018. Galangin Induces Apoptosis in MCF-7 Human Breast Cancer Cells Through Mitochondrial Pathway and Phosphatidylinositol 3-Kinase/Akt Inhibition. *Pharmacology*. 102(1-2), 58–66. doi:10.1159/000489564.
- Liu, T., Hwang, L., Burley, S.K., Nitsche, C.I., Southan, C., Walters, W.P., Gilson, M.K. 2025. BindingDB in 2024: a FAIR knowledgebase of protein-small molecule binding data, *Nucleic Acids Research*. Vol 53, Issue D1, D1633–D1644, <https://doi.org/10.1093/nar/gkae1075>.
- Lobert, S., Correia, J.J., 2000. Energetics of vinca alkaloid interactions with tubulin, in: *Methods in Enzymology*. Elsevier, pp. 77–103. [https://doi.org/10.1016/S0076-6879\(00\)23362-4](https://doi.org/10.1016/S0076-6879(00)23362-4)
- Lukasiewicz S, Czezelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. 2021. Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. *Cancers (Basel)*. 13(17):4287. doi: 10.3390/cancers13174287. PMID: 34503097; PMCID: PMC8428369.
- Lukey, M. J., Cluntun, A. A., Katt, W. P., Lin, M. J., Druso, J. E., Ramachandran, S., Cerione, R. A. 2019. Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer. *Cell Reports*. 29(1), 76–88.e7. doi:10.1016/j.celrep.2019.08.076
- Luo J, Zou H, Guo Y, Tong T, Ye L, Zhu C, Deng L, Wang B, Pan Y, Li P. 2022. SRC kinase-mediated signaling pathways and targeted therapies in breast cancer. *Breast Cancer Res*. 24(1):99. doi: 10.1186/s13058-022-01596-y. PMID: 36581908; PMCID: PMC9798727.
- Makanjuola, D., Alkushi, A., Alzaid, M., Abukhair, O., Al Tahan, F., Alhadab, A. 2014. Breast cancer in women younger than 30 years: prevalence rate and imaging findings in a symptomatic population. *Pan Afr Med J*. 19. 10.11604/pamj.2014.19.35.2849.
- Mayer IA, Arteaga CL. 2016. The PI3K/AKT Pathway as a Target for Cancer Treatment. *Annu Rev Med*. 67:11-28. doi:

10.1146/annurev-med-062913-051343. Epub 2015 Oct 14. PMID: 26473415.

MCF-7 | ATCC [WWW Document], 2024. URL <https://www.atcc.org/products/htb-22>(accessed 6.24.24).

Meng X, Laidler LL, Kosmacek EA, Yang S, Xiong Z, Zhu D, Wang X, Dai D, Zhang Y, Wang X, Brachova P, Albitar L, Liu D, Ianzini F, Mackey MA, Leslie KK. 2013. Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53. *Gynecol Oncol.* 128(3):461-9. doi: 10.1016/j.ygyno.2012.11.004. Epub 2012 Nov 9. PMID: 23146687; PMCID: PMC3612022.

Meiyanto, E., Melannisa, R., & Da'i, M. 2006. PGV-1 menurunkan ekspresi faktor angiogenesis (VEGF dan COX-2) pada sel T47D terinduksi estrogen. *Majalah Farmasi Indonesia.* 17(1), 1–6.

Meiyanto, E., Putri, D.D., Susidarti, R.A., Murwanti, R., Sardjiman, Fitriyani, A., Husnaa, U., Purnomo, H., dan Kawaichi, M. 2014. Curcumin and its analogues (PGV-0 and PGV-1) enhance sensitivity of resistant MCF-7 cells to doxorubicin through inhibition of HER2 and NF- κ B activation. *Asian Pac J Cancer Prev.* 15(1):179-84. doi: 10.7314/apjcp.2014.15.1.179. PMID: 24528023.

Meiyanto, E., Septisetyani, E. P., Larasati, Y. A., & Kawaichi, M. 2018. Curcumin analog pentagamavunon-1 (PGV-1) sensitizes widr cells to 5-fluorouracil through inhibition of NF- κ B activation. *Asian Pacific Journal of Cancer Prevention.* <https://doi.org/10.22034/APJCP.2018.19.1.49>.

Meiyanto E, Putri H, Arum Larasati Y, Yudi Utomo R, Istighfari Jenie R, Ikawati M. 2019. Anti-proliferative and Anti-metastatic Potential of Curcumin Analogue, Pentagamavunon- 1 (PGV-1), Toward Highly Metastatic Breast Cancer Cells in Correlation with ROS Generation. *Adv Pharm Bull.* 9(3):445–52.

Meiyanto E, Husnaa U, Kastian RF, Putri H, Larasati YA, Khumaira A, Pamungkas DDP, Jenie RI, Kawaichi M, Lestari B, Yokoyama T, Kato JY. 2021. The Target Differences of Anti-Tumorigenesis Potential of Curcumin and its Analogues Against HER-2 Positive and Triple-Negative Breast Cancer Cells. *Adv Pharm Bull.* 11(1):188-196. doi: 10.34172/apb.2021.020. Epub 2020 Nov 7. PMID: 33747866; PMCID: PMC7961225.

- Milosavljevic, N., Duranton, C., Djerbi, N., Puech, P., Gounon, P. and Lagadic Gossman, D. 2010. Nongenomic Effects Of Cisplatin: Acute Inhibition Of Mechanosensitive Transporters and Channels Without Actin Remodeling. *Mol Cell Pathobiol.* 70(19),7514–7522.
- Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeger H. 2017. Combination therapy in combating cancer. *Oncotarget.* 8(23):38022-38043. doi: 10.18632/oncotarget.16723. PMID: 28410237; PMCID: PMC5514969.
- Moreira, H., Szyjka, A., Paliszkiwicz, K., Barg, E., 2019. Prooxidative Activity of Celastrol Induces Apoptosis, DNA Damage, and Cell Cycle Arrest in Drug-Resistant Human Colon Cancer Cells. *Oxid. Med. Cell. Longev.* 1–12. <https://doi.org/10.1155/2019/6793957>
- Musyayyadah, H., Wulandari, F., Nangimi, A.F., Anggraeni, A., Ikawati, M., Meiyanto, E. 2021. The Growth Suppression Activity of Diosmin and PGV-1 Co-Treatment on 4T1 Breast Cancer Targets Mitotic Regulatory Proteins. *Asian Pac. J. Cancer Prev.* 22, 2929–2938. <https://doi.org/10.31557/APJCP.2021.22.9.2929>.
- Nagahama K., Utsumi T., Kumano T., Maekawa S., Oyama N., Kawakami J. 2016. Discovery of a new function of curcumin which enhances its anticancer therapeutic potency. *Sci. Rep.* 6:30962. doi: 10.1038/srep30962.
- Nickel J, Gohlke BO, Erehman J, Banerjee P, Rong WW, Goede A, Dunkel M, Preissner R. 2014. SuperPred: update on drug classification and target prediction. *Nucleic Acids Res.* W26-31. doi: 10.1093/nar/gku477. Epub 2014 May 30. PMID: 24878925; PMCID: PMC4086135.
- Novitasari, D., Meiyanto, E., Kato, J., dan Jenie, R. I. 2022. Antimigratory Evaluation from Curcumin-Derived Synthetic Compounds PGV-1 and CCA-1.1 on HCC1954 and MDA-MB-231 Cells. *Indonesian Journal of Cancer Chemopreventioan.* 13(2), 71-82.
- Novitasari, D., Kato, J., Ikawati, M., Putri, D. D. P., Wulandari, F., Widyarini, S., Zulfin, U.M., Salsabila, D. U., dan Meiyanto, E. 2023. PGV-1 permanently arrests HepG2 cells in M phase and inhibits liver carcinogenesis in DMH-induced rats. *Journal of Applied Pharmaceutical Science.* 13(8), 204–211.
- Pabla, N., Huang, S., Mi, Q.S., Daniel, R., and Dong, Z. 2008. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. *J. Biol. Chem.* 283, pp. 6572-6583

- Pan, H., Chen, J., Shen, K., Wang, X., Wang, P., Fu, G. 2015. Mitochondrial modulation by Epigallocatechin 3-Gallate ameliorates cisplatin induced renal injury through decreasing oxidative/nitrative stress, inflammation and NF- κ B in mice. *PloS One*. 10(4), e0124775.
- Patrick R. C., dan Maurer, B. J. 2005. Evaluating response to antineoplastic drug combinations in tissue culture models. *Chemosensitivity*. Volume 1 In Vitro Assays, 173-183.
- Partridge, A.H., Burstein, H.J., Winer, E.P. 2001. Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. *J Natl Cancer Inst Monogr*. (30):135–42.
- Plana D, Palmer AC, Sorger PK. 2022. Independent Drug Action in Combination Therapy: Implications for Precision Oncology. *Cancer Discov*. 12(3):606-624. doi: 10.1158/2159-8290.CD-21-0212. PMID: 34983746; PMCID: PMC8904281.
- Plesca D, Mazumder S, Almasan A. 2008. DNA damage response and apoptosis. *Methods Enzymol*. 446:107-22. doi: 10.1016/S0076-6879(08)01606-6. PMID: 18603118; PMCID: PMC2911482.
- Prayogo, A. A., Wijaya, A. Y., Hendrata, W. M., Looi, S. S., I'tishom, R., Hakim, L., Rantam, F. A., Sudiana, I. K., & Abdurachman, A. 2020. Dedifferentiation of MCF-7 Breast Cancer Continuous Cell Line, Development of Breast Cancer Stem Cells (BCSCs) Enriched Culture and Biomarker Analysis. *The Indonesian Biomedical Journal*. 12(2), 165–176. <https://doi.org/10.18585/inabj.v12i2.977>
- Provan, K.G., Leischow, S.J., Keagy, J., Nodora, J. 2010. Research collaboration in the discovery, development, and delivery networks of a statewide cancer coalition. *Eval. Program Plann*. <https://doi.org/10.1016/j.evalprogplan.2009.12.005>.
- Qodria, L., Utomo, R. Y., Hermawan, A., & Meiyanto, E. 2022. Anti-proliferative effects of pentagamaboronon-0-sorbitol on HER2-overexpressing breast cancer cells. *Indonesian Journal of Biotechnology*. 27(2), 58-64.
- Qu K, Lin T, Wei J, Meng F, Wang Z, Huang Z, Wan Y, Song S, Liu S, Chang H, Dong Y, Liu C. 2013. Cisplatin induces cell cycle arrest and senescence via upregulating P53 and P21 expression in

- HepG2 cells. *Nan Fang Yi Ke Da Xue Xue Bao*. 33(9):1253-9. PMID: 24067199.
- Rahmawati, D. R., Nurrochmad, A., Jenie, R. I., and Meiyanto, E. 2023. The Synergistic Cytotoxic Effect of Pentagamavunon-1 (PGV-1) and Curcumin Correlates with the Cell Cycle Arrest to Induce Mitotic Catastrophe in 4T1 and T47D Breast Cancer Cells. *The Indonesian Biomedical Journal*. 15(5); p.296-350.
- Rajappa, S., Singh, M., Uehara, R., Schachterle, S. E., & Setia, S. 2023. Cancer incidence and mortality trends in Asia based on regions and human development index levels: an analyses from GLOBOCAN 2020. *Current Medical Research and Opinion*. 39(8), 1127–1137. <https://doi.org/10.1080/03007995.2023.2231761>.
- Rathinam, R., Ghosh, S., Neumann, W. 2015. Cisplatin-induced apoptosis in auditory, renal, and neuronal cells is associated with nitration and downregulation of LMO4. *Cell Death Discovery*. 1, 15052. <https://doi.org/10.1038/cddiscovery.2015.52>
- Ren, K., Zhang, W., Wu, G., Ren, J., Lu, H., Li, Z., & Han, X. 2016. Synergistic anti-cancer effects of galangin and berberine through apoptosis induction and proliferation inhibition in oesophageal carcinoma cells. *Biomedicine & Pharmacotherapy*. 84, 1748–1759. doi:10.1016/j.biopha.2016.10.111
- Ren, J. X., Gong, Y., Ling, H., Hu, X., & Shao, Z. M. 2019. Racial/ethnic differences in the outcomes of patients with metastatic breast cancer: contributions of demographic, socioeconomic, tumor and metastatic characteristics. *Breast Cancer Research and Treatment*. 173(1), 225–237. <https://doi.org/10.1007/s10549-018-4956-y>.
- Rifai, F.N.P., Zulfin, U.M., Tafrohani, A.S., Ikawati, M., Meiyanto, E. 2024a. Hesperidin Enhanced the Antimigratory Activity and Senescence Mediated G2/M Arrest Effect of PGV-1 Against T47D Luminal Breast Cancer Cells. *Indonesian Journal of Pharmacy*. 35 (1).
- Rifai, F.N.P., Hanifa, M., Zulfin, U.M., Ikawati, M., Meiyanto, E. 2024b. Hesperitin Synergistically Promotes the Senescence Induction of Pentagamavunone-1 in Luminal Breast Cancer Cells, T47D. *Journal of Tropical Biodiversity and Biotechnology*. 9(01). doi: <https://doi.org/10.22146/jtbb.88238>.
- Robert S. DiPaola. 2002. To Arrest or Not To G2-M Cell-Cycle Arrest. *Clinical Cancer Research*, 8 (November), 3311–3314.

- Robinson TP, Ehlers T, Hubbard IV RB, Bai X, Arbiser JL, Goldsmith DJ, Bowen JP. 2003. Design, synthesis, and biological evaluation of angiogenesis inhibitors: aromatic enone and dienone analogues of curcumin. *Bioorg Med Chem Lett.* 13(1):115-7. doi: 10.1016/s0960-894x(02)00832-6. PMID: 12467629.
- Rouzier R., Rajan R., Wagner P., Hess K.R., Gold D.L., Stec J., Ayers M., Ross J.S., Zhang P., Buchholz T.A. 2005. Microtubule-Associated Protein Tau: A Marker of Paclitaxel Sensitivity in Breast Cancer. *Proc. Natl. Acad. Sci.* 102:8315–8320. doi: 10.1073/pnas.0408974102.
- Safran, M., Rosen, N., Twik, M., BarShir, R., Stein, T. I., Dahary, D. 2021. “The GeneCards suite,” in Practical guide to life science databases. *Springer Nature Singapore.* 27–56. doi:10.1007/978-981-16-5812-9_2.
- Salaun P, Rannou Y, Prigent C. 2008. Cdk1, Plks, Auroras, and Neks: the mitotic bodyguards. *Adv Exp Med Biol.* 617:41-56. doi: 10.1007/978-0-387-69080-3_4. PMID: 18497029; PMCID: PMC2533106.
- Sarin N, Engel F, Kalayda GV, Mannewitz M, Cinatl J Jr. 2017. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest. *PLOS ONE.* 12(7): e0181081. <https://doi.org/10.1371/journal.pone.0181081>
- Schuler M, Green DR. 2001. Mechanisms of p53-dependent apoptosis. *Biochem Soc Trans.* 29(Pt 6):684-8. doi: 10.1042/0300-5127:0290684. PMID: 11709054.
- Setyowibowo, H., Purba, F. D., Hunfeld, J. A. M., Iskandarsyah, A., Sadarjoen, S. S., Passchier, J., & Sijbrandij, M. 2018. Quality of life and health status of Indonesian women with breast cancer symptoms before the definitive diagnosis: A comparison with Indonesian women in general. *PLoS ONE.* 13(7), 1–11. <https://doi.org/10.1371/journal.pone.0200966>.
- Shah MA, Schwartz GK. 2001. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. *Clin Cancer Res.* 7(8):2168-81. PMID: 11489790.
- Shen, D.-W., Pouliot, L. M., Hall, M. D., & Gottesman, M. M. 2012. Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes.

- Pharmacological Reviews.* 64(3), 706–721.
doi:10.1124/pr.111.005637
- Siddik, Z. 2003. Cisplatin: mode of cytotoxic action and molecular basis of resistance. *Oncogene.* 22, 7265–7279 .
<https://doi.org/10.1038/sj.onc.1206933>
- Sinnarkar S, Suryawanshi P, Dilip A, Bhawalkar J, Ladke V. 2024. Galangin promotes apoptosis by upregulating the pro-apoptotic gene BAX in triple-negative breast cancer. *J Egypt Natl Canc Inst.* 20;36(1):41. doi: 10.1186/s43046-024-00246-y. PMID: 39702881.
- Song, W.; Yan, C.-Y.; Zhou, Q.-Q.; Zhen, L.-L. 2017. Galangin potentiates human breast cancer to apoptosis induced by TRAIL through activating AMPK. *Biomed. Pharmacother.* 89, 845–856.
- Spoerri, L., Oo, Z.Y., Larsen, J.E., Haass, N.K., Gabrielli, B., Pavey, S., 2015. Cell Cycle Checkpoint and DNA Damage Response Defects as Anticancer Targets: From Molecular Mechanisms to Therapeutic Opportunities, in: Wondrak, G.T. (Ed.), *Stress Response Pathways in Cancer.* Springer Netherlands, Dordrecht, pp. 29–49. https://doi.org/10.1007/978-94-017-9421-3_3
- Suenaga, N., Kuramitsu, M., Komure, K., Kanemaru, A., Takano, K., Ozeki, K., Jono, H. 2019. Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell Carcinoma. *International Journal of Molecular Sciences.* 20(20), 5194. doi:10.3390/ijms20205194
- Swift, L.P., Rephaeli, A., Nudelman, A., Phillips, D.R., Cutts, S.M. 2006. Doxorubicin-DNA Adducts Induce a Non-Topoisomerase II-Mediated Form of Cell Death. *Cancer Res.* 66, 4863–4871. <https://doi.org/10.1158/0008-5472.CAN-05-3410>
- Szklarczyk, D., Gable, A.L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J. 2019. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res.* 47(D1):D607–13.
- Tantawy SI, Timofeeva N, Sarkar A, Gandhi V. 2023. Targeting MCL-1 protein to treat cancer: opportunities and challenges. *Front Oncol.* 13:1226289. doi: 10.3389/fonc.2023.1226289. PMID: 37601693; PMCID: PMC10436212.
- Telli ML, Tolaney SM, Shapiro GI, Middleton M, Lord SR, Arkenau HT, Tutt A, Abramson V, Dean E, Haddad TC, Wesolowski R, Ferrer-Playan J, Goddemeier T, Grombacher T, Dong J,

- Fleuranceau-Morel P, Diaz-Padilla I, Plummer R. 2022. Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer. *NPJ Breast Cancer*. 8(1):45. doi: 10.1038/s41523-022-00406-0. PMID: 35393425; PMCID: PMC8991212.
- Thomas, R., & Weihua, Z.. 2019. Rethink of EGFR in Cancer With Its Kinase Independent Function on Board. *Frontiers in Oncology*. 9, 468754. <https://doi.org/10.3389/fonc.2019.00800>
- Tomar, A., Vasisth, S., Khan, S. I., Malik, S., Nag, T. C., Arya, D. S., & Bhatia, J. 2017. Galangin ameliorates cisplatin induced nephrotoxicity in vivo by modulation of oxidative stress, apoptosis and inflammation through interplay of MAPK signaling cascade. *Phytomedicine*. 34, 154–161. doi:10.1016/j.phymed.2017.05.0
- Todd, R.C., and Lippard, S.J. 2009. Inhibition of transcription by platinum antitumor compounds. *Metallomics*. 1, pp. 280-291.
- Tomeh, M., Hadianamrei, R., Zhao, X. 2019. A Review of Curcumin and Its Derivatives as Anticancer Agents. *Int. J. Mol. Sci.* 20, 1033. <https://doi.org/10.3390/ijms20051033>.
- Tonnesen HH and Karlsten J. 1995. High Performance Liquid Chromatography of Curcumin and Related Compound. *J Chrom*. 259: 367 – 371.
- Tsukamoto M., Kuroda K., Ramamoorthy A., Yasuhara K. 2014. Modulation of raft domains in a lipid bilayer by boundary-active curcumin. *Chem. Commun.* 50:3427–3430. doi: 10.1039/c3cc47738j.
- Tuli HS, Sak K, Adhikary S, Kaur G, Aggarwal D, Kaur J, Kumar M, Parashar NC, Parashar G, Sharma U, Jain A. 2022. Galangin: A metabolite that suppresses anti-neoplastic activities through modulation of oncogenic targets. *Exp Biol Med (Maywood)*. 247(4):345-359. doi: 10.1177/15353702211062510. Epub 2021 Dec 14. PMID: 34904901; PMCID: PMC8899339.
- Van der Goot, H. 1997. The Chemistry and Qualitative Structure Activity Relationships of Curcumin. *Proceeding of the International Symposium on Curcumin Pharmacochimistry (ISCP)*. August 29 – 31, 1995. Yogyakarta, Indonesia., p. 13 – 26.
- Velma V, Dasari SR, Tchounwou PB. 2016. Low Doses of Cisplatin Induce Gene Alterations, Cell Cycle Arrest, and Apoptosis in Human Promyelocytic Leukemia Cells. *Biomark Insights*. 11:113-21. doi: 10.4137/BMI.S39445. PMID: 27594783; PMCID: PMC4998075.

- Wang, LH., Li, Y., Yang, SN. 2014. Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF- κ B and MAPK/HO-1 signalling. *Br J Cancer*. 110, 341–352 . <https://doi.org/10.1038/bjc.2013.752>
- Wang P, Cui J, Wen J, Guo Y, Zhang L, Chen X. 2016a. Cisplatin induces HepG2 cell cycle arrest through targeting specific long noncoding RNAs and the p53 signaling pathway. *Oncol Lett*. 12(6):4605-4612. doi: 10.3892/ol.2016.5288. Epub 2016 Oct 18. PMID: 28105167; PMCID: PMC5228559.
- Wang, Z., Liang, L., Yin, Z. 2016b. Improving chemical similarity ensemble approach in target prediction. *J Cheminform*. 8, 20. <https://doi.org/10.1186/s13321-016-0130-x>
- Wang, H., and Tang, C. 2017. Galangin suppresses human laryngeal carcinoma via modulation of caspase-3 and AKT signaling pathways. *Oncology Reports*. 38, 703-714. <https://doi.org/10.3892/or.2017.5767>.
- Wang, Y., Lin, B., Lin, L., Lan, H., Yu, S., Wu, J., Zhang, H. 2017. Galangin suppresses hepatocellular carcinoma cell proliferation by reversing the Warburg effect. *Biomed. Pharmacother*. 95, pp. 1295-1300, [10.1016/j.biopha.2017.09.056](https://doi.org/10.1016/j.biopha.2017.09.056)
- Wang T, Lu J, Wang R, Cao W, Xu J. 2022a. TOP2A promotes proliferation and metastasis of hepatocellular carcinoma regulated by miR-144-3p. *J Cancer*. 13(2):589-601. doi:10.7150/jca.64017. <https://www.jcancer.org/v13p0589.htm>
- Wang, X., Wang, J., Lyu, L. 2022b. Oncogenic role and potential regulatory mechanism of topoisomerase II α in a pan-cancer analysis. *Sci Rep* 12, 11161. <https://doi.org/10.1038/s41598-022-15205-7>
- Wang, H., Guo, M., Wei, H. 2023. Targeting p53 pathways: mechanisms, structures and advances in therapy. *Sig Transduct Target Ther*. 8, 92. <https://doi.org/10.1038/s41392-023-01347-1>
- Wei, C., Zhang, L., Yang, W., & Zhu, X. 2016. p53 inhibits the expression of p125 and the methylation of POLD1 gene promoter by downregulating the Sp1-induced DNMT1 activities in breast cancer. *OncoTargets and Therapy*. 1351. doi:10.2147/ott.s98713.
- Weinberg, R.A. 2007. Is metastasis predetermined? *Mol. Oncol*. 1, 263–264. <https://doi.org/10.1016/j.molonc.2007.07.001>.
- Weiss RB, Christian MC. 1993. New cisplatin analogues in development. A review. *Drugs*. 46(3):360-377. doi:

- 10.2165/00003495-199346030-00003. *Erratum in: Drugs*. 46(3):377. PMID: 7693428.
- World Health Organization (WHO). 2022. Breast Cancer. <https://www.who.int/news-room/fact-sheets/detail/breast-cancer>.
- Wulandari F, Ikawati M, Kirihata M, Kato J-Y, Meiyanto E. 2021. Curcumin Analogs, PGV-1 and CCA-1.1 Exhibit Anti-migratory Effects and Suppress MMP9 Expression on WiDr Cells. *The Indonesian Biomedical Journal*. 13(3):271–80.
- Xu, H., Wang, Q., & Fan, G.-K. 2020. The Antiproliferative and Antifibrotic Effects of Cisplatin on Primary Human Vocal Fold Fibroblasts. *ORL J Otorhinolaryngol Relat Spec*. 1–13. doi:10.1159/000506708
- Yang Z, Li X, Han W, Lu X, Jin S, Yang W, Li J, He W, Qian Y. 2017. Galangin suppresses human osteosarcoma cells: an exploration of its underlying mechanism. *Oncol Rep*. 37:435–41.
- Yang J, Kang H, Lyu L, Xiong W, Hu Y. 2023. A target map of clinical combination therapies in oncology: an analysis of clinicaltrials.gov. *Discov Oncol*. 14(1):151. doi: 10.1007/s12672-023-00758-4. PMID: 37603124; PMCID: PMC10441974.
- Yap, T.A., Omlin, A., de Bono, J.S. 2013. Development of therapeutic combinations targeting major cancer signaling pathways. *J Clin Oncol*. (31):1592–605.
- Yersal, O., 2014. Biological subtypes of breast cancer: Prognostic and therapeutic implications. *World J. Clin. Oncol*. 5, 412. <https://doi.org/10.5306/wjco.v5.i3.412>
- Yu, S., Gong, L., Li, N., Pan, Y., and Zhang, L. 2018. Galangin (GG) combined with cisplatin (DDP) to suppress human lung cancer by inhibition of STAT3-regulated NF-κB and Bcl-2/Bax signaling pathways. *Biomedicine & Pharmacotherapy*. Volume 97. Pages 213-224. ISSN 0753-3322. <https://doi.org/10.1016/j.biopha.2017.10.059>.
- Zhang, W., Huang, Q., dan Hua, Z. 2012. Galangin and TRAIL cooperate to suppress A549 lung cancer proliferation via apoptosis and p38 MAPK activation. *Acta Pharmaceutica Sinica B*. 2(6), <https://doi.org/10.1016/j.apsb.2012.10.009>.
- Zhang C, Luo CL, Shang GS, Jiang DX, Song Q. 2021. Galangin Enhances Anticancer Efficacy of 5-Fluorouracil in Esophageal Cancer Cells

and Xenografts Through NLR Family Pyrin Domain Containing 3 (NLRP3) Downregulation. *Med Sci Monit.* 27:e931630. doi: 10.12659/MSM.931630. PMID: 34916479; PMCID: PMC8690210.

Zhao, Y., Jing, Z., Li, Y., & Mao, W. 2016. Berberine in combination with cisplatin suppresses breast cancer cell growth through induction of DNA breaks and caspase-3-dependent apoptosis. *Oncology Reports.* 36, 567-572. <https://doi.org/10.3892/or.2016.4785>.

Zhu, L., Luo, Q., Bi, J., Ding, J., Ge, S., & Chen, F. 2014. Galangin inhibits growth of human head and neck squamous carcinoma cells in vitro and in vivo. *Chemico-Biological Interactions.* 224, 149-156. <https://doi.org/10.1016/j.cbi.2014.10.027>

Zhu X, Feng J, Fu W, Shu X, Wan X, Liu J. 2020. Effects of cisplatin on the proliferation, invasion and apoptosis of breast cancer cells following β -catenin silencing. *Int J Mol Med.* 45(6):1838-1850. doi: 10.3892/ijmm.2020.4543. Epub 2020 Mar 16. PMID: 32186756; PMCID: PMC7169654.

Ziegler DV, Parashar K, Fajas L. 2024. Beyond cell cycle regulation: The pleiotropic function of CDK4 in cancer. *Semin Cancer Biol.* Jan;98:51-63. doi: 10.1016/j.semcancer.2023.12.002. Epub 2023 Dec 20. PMID: 38135020.

Zou J., Zhu L., Jiang X., Wang Y., Wang Y., Wang X., Chen B. 2018. Curcumin increases breast cancer cell sensitivity to cisplatin by decreasing FEN1 expression. *Oncotarget.* 9: 11268-11278